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SAVING LIVES: PREVENTING, FINDING, AND CURING 
CHILDHOOD AND ADOLESCENT TB AND HIV 
 
 
Out of the 10.4 million new global tuberculosis cases (TB) in 2015, 1 million occurred in children under 15 years of age, with at least 210,000 
child deaths when including children living with HIV1. Children living with HIV are more likely to die once infected with TB2 – the leading 
infectious cause of death among people living with HIV. Preventing, finding, and curing TB are critical to reducing childhood mortality, 
especially for HIV-infected children. 
 
The World Health Organization recommends that HIV programs routinely conduct intensified TB case-finding to diagnose all cases of TB; give 
TB preventive therapy and implement proper TB infection control measures to prevent additional TB cases; and provide optimal care for 
children (<15 years) and adolescents (15 to 19 years old) living with HIV. As part of support to country programs, the U.S. Centers for Disease 
Control and Prevention’s (CDC)  encourages the appropriate diagnosis, treatment, and prevention of TB in children and adolescents according 
to World Health Organization policy3,4,5 and national guidelines. 
 
 
 
 
 
CDC works with national Ministries of Health, HIV, and TB programs as well as multilateral and nongovernmental organizations to implement 
policies and programs and conduct research that support quality TB and HIV prevention, case-finding, and linkage to treatment for all children 
and adolescents. CDC also contributes to gathering and reporting global childhood TB and HIV data within the U.S. President’s Emergency Plan 
for AIDS Relief (PEPFAR). In fiscal year 2016, CDC partnered with other PEPFAR agencies to: 
 
1. Support TB screening for over 400,0006 children living with HIV 
2. Ensure that over 107,0007 children and adolescents with TB had documented HIV status 
3. Provide antiretroviral treatment (ART) to more than 21,0008 children with HIV and TB (Figure 1) 
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Figure 1: Courtesy of PEPFAR’s Interagency Collaborative for Program Improvement TB-HIV Global Dashboard 
(Data are included for children and adolescents with available age-disaggregated data) 
 
 
CDC’s priorities for childhood TB 
 
 Prevention of TB by encouraging the implementation of contact tracing to find and treat new TB cases early, and start TB preventive 
therapy in all eligible children and adolescents 
 Rapid, accurate diagnosis and treatment of TB 
 HIV testing for all people with TB and timely linkage to HIV treatment 
 Monitoring and evaluation of childhood TB prevention, diagnosis, and treatment programs 
 
 
 
 
 
Preventing TB 
 
 TB prevention in Kenya: CDC worked with the Kenya Ministry of Health and other stakeholders to implement and evaluate World 
Health Organization guidance for routine program activities for TB in people living with HIV, including children. After developing tools 
and procedures for implementing TB screening and preventive therapy, the Kenya Ministry of Health started TB preventive therapy for 
nearly half of 900,000 persons living with HIV. In CDC-supported sites, 80 percent of all people living with HIV are receiving TB 
preventive therapy. In an analysis of 3 clinics, 92 percent of all children starting preventive therapy finished therapy9. 
 
 Household HIV and TB screening in Mozambique and Uganda: CDC is working with partners in Mozambique and Uganda to 
implement contact tracing and conduct household-based screening for TB and HIV with linkage to appropriate prevention and 
treatment services for household contacts of people with TB and HIV. 
 
Rapid TB diagnosis and treatment 
 
 Diagnosing childhood TB in Kenya: CDC has collaborated with multiple partners, including the Kenya Medical Research Institute and 
Harvard University, to determine and optimize a feasible combination of non-invasive specimens for TB diagnosis in children. This 
study of 300 children with TB symptoms found the combination of less invasive stool and nasal wash specimens performed similarly to 
invasive TB tests, such as the collection of stomach fluid, that often require hospitalization and are rarely available in resource-poor 
settings. 
 
 Contributing to U.S. pediatric TB guidelines and international childhood TB guidance: CDC works with international 
organizations to contribute to national and international TB guidelines in children and adolescents. Most recently, CDC has 
contributed to developing a “Roadmap for childhood tuberculosis,” led updating of U.S. Health and Human Services pediatric TB 
guidance, contributed to the development of a blueprint for addressing gaps in childhood TB diagnostics, and informed revised 
childhood multi-drug resistant TB treatment guidelines with partner agencies. 
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HIV testing and linkage to treatment 
 
 Childhood TB surveillance in Vietnam: CDC collaborated with the National TB Program 
in Vietnam to evaluate surveillance, recording, and reporting in children. Only 25 percent 
of children treated for TB had an HIV test result documented in routine reporting systems 
compared to more than 90 percent of adults with HIV test results. The evaluation 
provided essential data not available through routine reporting and resulted in 
recommendations to improve routine HIV testing for children with TB. 
 
Monitoring and evaluation 
 
 Evaluation of HIV testing and TB contact tracing in Tanzania: CDC worked with the 
Tanzania National Tuberculosis Program to evaluate routine HIV testing in children with 
TB and document contact tracing completeness for adult TB patients. Through successful, 
routine HIV testing, more than 200 children with HIV were linked to care after their TB 
diagnosis. 
 
 
 
 
 
CDC continues to support national programs to improve rapid, accurate TB diagnosis, treatment, and quality monitoring and evaluation. CDC 
will also focus on strengthening TB contact tracing, early diagnosis of TB-exposed children with TB disease, and the provision of preventive 
therapy for all eligible children and adolescents to lower TB morbidity and mortality. 
 
 
 
 
 
Through these and other efforts, CDC identifies gaps in the prevention and treatment of TB in children and adolescents in the United States and 
globally. Using these results, CDC works with national programs to implement TB prevention activities, improve TB case-finding, and scale-up 
HIV testing for all populations at-risk, providing greater access to life-saving care for children and adolescents with TB and HIV. 
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